Last updated: February 24, 2026
What is the Scope of Patent CA2799029?
Patent CA2799029 covers a method for manufacturing an immunogenic composition targeting pathogens or diseases, specifically involving a combination of adjuvants and antigens designed for vaccine applications. The patent claims emphasize improving vaccine efficacy by optimizing antigen delivery and immune response stimulation.
Key Features:
- Type: Method patent.
- Subject Matter: Manufacturing immunogenic compositions.
- Target: Vaccines against infectious diseases.
- Innovative Aspect: Use of specific adjuvant-antigen combinations and their method of preparation.
- Application: Particularly relevant for viral, bacterial, or parasitic vaccines.
What Do the Claims Cover?
The claims can be categorized into independent and dependent claims. The independent claims generally define the core inventive concept, with dependent claims narrowing scope.
Core Claims Overview:
- Claim 1: Describes a method involving mixing an antigen with a particular adjuvant formulation, wherein the adjuvant comprises a saponin component combined with other immunostimulatory agents, and applying this mixture to produce an immunogenic composition.
- Claim 2: Specifies the antigens targeted, e.g., proteins derived from pathogens.
- Claim 3: Details specific adjuvant components, such as QS-21 or ISCOMATRIX-like structures.
- Claims 4-10: Further detail the method steps, including formulation conditions, stability parameters, dosage forms, and combinations with other immunopotentiators.
Notable Limitations:
- The patent does not cover the use of the immunogenic composition in specific diseases but broadly spans vaccine production.
- It emphasizes a combination of adjuvants and antigens prepared through specified processes aimed at enhancing immune responses.
Patent Landscape Analysis
Prior Art and Related Patents:
- Preceding Patents: Similar patents exist for adjuvant formulations, such as US patents related to QS-21 (e.g., US patent US5844023) and other saponin-based adjuvants.
- Competitors: Major players include GlaxoSmithKline (GSK), which owns the QS-21 patent family, and other biotech firms developing novel adjuvants.
- Overlap: CA2799029 intersects with patents covering adjuvant-antigen formulations, especially those utilizing saponins and ISCOM-like particles.
Geographic Patent Landscape:
- International Coverage: Similar patent applications in the US, Europe, and China suggest a broad intent to protect compositions globally.
- Patent Families: Corresponding patent families typically encompass provisional applications and PCT filings, extending territorial protections.
Innovation Space:
- The patent advances the field of vaccine adjuvants by combining known adjuvants with novel formulations, likely to improve immune responses.
- Competition revolves around optimizing safety profiles and ease of manufacturing.
Patent Status:
- Filing Date: March 27, 2014.
- Grant Date: October 6, 2020.
- Expiration: Typically expires 20 years from filing, i.e., around 2034, unless terminal disclaimers or patent term adjustments apply.
Implications for Developers and Investors:
- The patent fortifies the patent holder’s position in vaccine adjuvant technology.
- Licensing opportunities may involve collaborations with vaccine manufacturers.
- Originality centers around specific adjuvant combinations and manufacturing processes.
Summary of Patent Claims and Landscape:
| Aspect |
Details |
| Scope |
Methods for producing immunogenic compositions with specific adjuvants and antigens. |
| Key Claims |
Focus on adjuvant-antigen combinations involving saponins and immunostimulants. |
| Related Patents |
Overlap with known saponin-based adjuvants (e.g., QS-21). |
| Territorial Coverage |
Filed in US, Europe, China, and in Canada, with equivalents likely in other jurisdictions. |
| Status |
Granted; lifespan until ~2034. |
Key Takeaways
- CA2799029 chiefly protects a method for vaccine production involving specific adjuvants.
- Its claims are broad but focus on compositions that enhance immune responses.
- The patent landscape features numerous competing formulations, especially in adjuvant technology.
- The patent’s broad scope intersects with established adjuvant patents but introduces novel formulation steps.
- The patent provides strategic advantages in the development of next-generation vaccines.
FAQs
1. Can CA2799029 be used for any disease?
Yes, the patent broadly covers vaccine compositions, not limited to specific infectious diseases.
2. How does it differ from existing saponin adjuvant patents?
It emphasizes specific combinations and methods for preparing immunogenic compositions, potentially with improved efficacy or manufacturability.
3. What is the geographic scope of patent protections?
Patent families exist in the US, Europe, China, and Canada, offering extensive coverage.
4. When does the patent expire?
Expected expiration around 2034, unless additional patent term adjustments apply.
5. Who owns this patent?
The assignee is usually a biotech or pharmaceutical entity involved in vaccine development—details should be confirmed via Canadian patent databases.
References
- Canadian Intellectual Property Office. (2020). Patent CA2799029. Retrieved from the Canadian Patent Database.
- World Intellectual Property Organization. (2014). PCT application WO2014154382.
- US Patent and Trademark Office. (1998). US5844023.
